While we’re catching a high-risk population through preventive screenings, we are also identifying an entirely separate high-risk population: children of the patients that were just screened and found to have high risk polyps such as greater than 1 cm or with certain advanced characteristics.
Little things truly matter. This is especially true in our fight to prevent colon cancer. Colon cancer almost always starts as tiny mushroom-looking, pre-cancerous growths called “polyps”. Over a five- to 10-year period, these little 1mm-10mm nothings may evolve into something…cancer. Fortunately, these can be easily removed during a colonoscopy.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A colonoscopy has never been advertised as a pleasant experience. However, it’s an important procedure and awareness for detecting cancer early on is essential. Turns out, all people really need in order to be proactive is a slight financial nudge – the potential for a $50 reward. In a new study led by a researcher at […]
Medicare beneficiaries may get speedier coverage for a newly approved screening test for colorectal cancer under a pilot project in which two federal agencies reviewed the product at the same time instead of one after the other. The Cologuard test, which detects the presence of DNA mutations that may be cancers in the stool, was approved […]
“MedCity News has partnered with BioCrossroads to provide coverage focused on Indiana’s next generation of growth and innovation in life sciences” An Indiana life sciences company looks at metabolites as snapshots to diagnose and monitor cancer. The idea is that cancerous cells have distinct differences in metabolism than healthy cells. Matrix-Bio, a startup with corporate […]
There’s a new biotech startup in town: Kodosil Bio. The by-product of a licensing deal between San Diego biologics developer BioAtla and Cleveland-based biotech incubator BioMotiv, the company will focus on development of a monoclonal antibody for inflammatory bowel diseases and cancers. For now, details are pretty scant on the new company. According to a […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
“Most companies have come out of particular biological research and picked one horse to bet on,” said John Blume in explaining his company’s approach to developing a cancer diagnostic. “We’ve built a technology platform that takes a wide-angle view and lets data tell us what wins.” Blume is the chief scientific officer of Applied Proteomics […]